Articles published by Enveda

Enveda Advances Third Asset to the Clinic With US FDA IND Clearance and Phase 1 Initiation of ENV-6946, a First-in-Class Oral “Multi-Biologic in a Pill” for Inflammatory Bowel Disease

December 23, 2025

From Enveda

Via Business Wire

Enveda Announces US FDA IND Clearance and First Patient Dosed in Phase 1 Trial of ENV-308, a First-in-Class Oral Therapy for Obesity; Appoints Nadeem Sarwar, Ph.D., MPharm, MPhil, to Lead Metabolic Disease Strategy

December 17, 2025

From Enveda

Via Business Wire

Enveda Initiates Phase 2 Clinical Trials of ENV-294, a First-in-Class Oral Therapy in Atopic Dermatitis and Asthma

December 09, 2025

From Enveda

Via Business Wire

Enveda Raises $150M Series D Funding to Reach Unicorn Status, Enrolls First Patient in Lead Program, and Adds Mikael Dolsten to Board of Directors

September 04, 2025

From Enveda

Via Business Wire

Enveda Reports Favorable Phase 1 Safety for Novel Oral Anti-Inflammatory, Launches Phase 1b Trial in Atopic Dermatitis

May 28, 2025

From Enveda

Via Business Wire

Enveda Gains Backing from Sanofi to Advance AI-Driven Drug Discovery to Clinical Trials Bringing Total Series C Financing to $150M

February 26, 2025

From Enveda

Via Business Wire

Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board

February 05, 2025

From Enveda

Via Business Wire

Enveda Welcomes Jason Kim as Chief Financial Officer

January 10, 2025

From Enveda

Via Business Wire

Enveda Closes $130M Series C Funding to Deliver Multiple Clinical Readouts from a Pipeline of 10 Development Candidates

November 21, 2024

From Enveda

Via Business Wire

Enveda Announces First Candidate Discovered From Nature Using AI Advances to Clinical Trials

November 13, 2024

From Enveda

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.